| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomarkers, Tumor | 12 | 2025 | 1660 | 0.770 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2025 | 361 | 0.660 |
Why?
|
| Mutation | 9 | 2025 | 4272 | 0.540 |
Why?
|
| Kidney Neoplasms | 4 | 2025 | 546 | 0.520 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2024 | 361 | 0.450 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2019 | 537 | 0.400 |
Why?
|
| Receptor, ErbB-2 | 3 | 2024 | 280 | 0.400 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2025 | 454 | 0.350 |
Why?
|
| Hodgkin Disease | 2 | 2023 | 145 | 0.320 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 423 | 0.310 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2025 | 379 | 0.280 |
Why?
|
| Immunohistochemistry | 4 | 2024 | 1799 | 0.270 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2025 | 826 | 0.270 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2019 | 81 | 0.260 |
Why?
|
| Leiomyoma | 2 | 2022 | 211 | 0.260 |
Why?
|
| Glioma | 2 | 2019 | 301 | 0.240 |
Why?
|
| Pleural Neoplasms | 2 | 2019 | 201 | 0.240 |
Why?
|
| MAP Kinase Signaling System | 1 | 2025 | 200 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2025 | 178 | 0.210 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2023 | 19 | 0.200 |
Why?
|
| Genes, myb | 1 | 2002 | 5 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2002 | 7 | 0.190 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 813 | 0.190 |
Why?
|
| Neurofibromin 2 | 1 | 2022 | 31 | 0.180 |
Why?
|
| Hematologic Diseases | 1 | 2022 | 77 | 0.180 |
Why?
|
| DNA Replication | 1 | 2002 | 168 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2025 | 2465 | 0.180 |
Why?
|
| Humans | 34 | 2025 | 93515 | 0.170 |
Why?
|
| Meningioma | 1 | 2022 | 62 | 0.170 |
Why?
|
| Meningeal Neoplasms | 1 | 2022 | 69 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 106 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 2 | 2020 | 1073 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 318 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 624 | 0.170 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 305 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 365 | 0.160 |
Why?
|
| DNA Mutational Analysis | 2 | 2025 | 543 | 0.160 |
Why?
|
| Middle Aged | 15 | 2025 | 27573 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 409 | 0.160 |
Why?
|
| STAT6 Transcription Factor | 1 | 2019 | 29 | 0.160 |
Why?
|
| Gene Rearrangement | 2 | 2019 | 168 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2020 | 33 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2020 | 33 | 0.150 |
Why?
|
| Aged, 80 and over | 8 | 2025 | 7061 | 0.150 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2019 | 20 | 0.150 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2019 | 15 | 0.150 |
Why?
|
| Aged | 12 | 2025 | 20434 | 0.150 |
Why?
|
| Gene Duplication | 2 | 2012 | 128 | 0.150 |
Why?
|
| Adult | 14 | 2025 | 27918 | 0.150 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 381 | 0.140 |
Why?
|
| Osteosarcoma | 1 | 2020 | 158 | 0.140 |
Why?
|
| Stromal Cells | 1 | 2019 | 151 | 0.140 |
Why?
|
| Database Management Systems | 1 | 2018 | 44 | 0.140 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 34 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 1077 | 0.140 |
Why?
|
| Female | 17 | 2025 | 48702 | 0.130 |
Why?
|
| Medical Informatics | 1 | 2018 | 48 | 0.130 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 521 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 402 | 0.130 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 9 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 134 | 0.130 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 260 | 0.130 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 313 | 0.130 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 53 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 603 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 797 | 0.130 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2017 | 83 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 11 | 0.130 |
Why?
|
| Male | 16 | 2025 | 44557 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1234 | 0.120 |
Why?
|
| Trans-Activators | 1 | 2019 | 439 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2019 | 184 | 0.120 |
Why?
|
| Rhabdoid Tumor | 1 | 2016 | 21 | 0.120 |
Why?
|
| Monosomy | 1 | 2016 | 12 | 0.120 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2016 | 66 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 939 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 38 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 1338 | 0.120 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 18 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2016 | 83 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 537 | 0.120 |
Why?
|
| Urothelium | 1 | 2016 | 67 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 74 | 0.120 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2016 | 91 | 0.110 |
Why?
|
| Urologic Neoplasms | 1 | 2016 | 78 | 0.110 |
Why?
|
| Quinazolines | 1 | 2016 | 211 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 344 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 666 | 0.110 |
Why?
|
| Leukemia | 1 | 2017 | 301 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 298 | 0.110 |
Why?
|
| Genomics | 2 | 2017 | 848 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 636 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 308 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 1713 | 0.100 |
Why?
|
| Neuroblastoma | 1 | 2017 | 396 | 0.100 |
Why?
|
| Mesothelioma | 1 | 2016 | 331 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2017 | 456 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2012 | 6 | 0.100 |
Why?
|
| Myopathies, Structural, Congenital | 1 | 2012 | 11 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 1275 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2024 | 10164 | 0.090 |
Why?
|
| Young Adult | 5 | 2024 | 6930 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2011 | 40 | 0.090 |
Why?
|
| Adolescent | 5 | 2024 | 9606 | 0.090 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 41 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2016 | 697 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2715 | 0.080 |
Why?
|
| Prognosis | 3 | 2025 | 3911 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2018 | 1691 | 0.080 |
Why?
|
| Genetic Testing | 3 | 2022 | 565 | 0.080 |
Why?
|
| Biomarkers | 1 | 2016 | 1910 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 767 | 0.070 |
Why?
|
| Phenotype | 3 | 2019 | 2544 | 0.060 |
Why?
|
| NF-kappa B | 2 | 2019 | 408 | 0.060 |
Why?
|
| raf Kinases | 1 | 2025 | 15 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2025 | 50 | 0.060 |
Why?
|
| Karyotyping | 1 | 2025 | 222 | 0.060 |
Why?
|
| Clone Cells | 1 | 2025 | 219 | 0.060 |
Why?
|
| Intellectual Disability | 1 | 2006 | 195 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2016 | 2479 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 889 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 985 | 0.060 |
Why?
|
| GTP Phosphohydrolases | 1 | 2025 | 80 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1448 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2024 | 140 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2025 | 162 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 2365 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 204 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2002 | 20 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2023 | 132 | 0.050 |
Why?
|
| S Phase | 1 | 2002 | 64 | 0.050 |
Why?
|
| G1 Phase | 1 | 2002 | 64 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 108 | 0.050 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2022 | 9 | 0.050 |
Why?
|
| Chickens | 1 | 2002 | 206 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2002 | 186 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2025 | 3502 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 288 | 0.040 |
Why?
|
| Germ Cells | 1 | 2022 | 130 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2019 | 3054 | 0.040 |
Why?
|
| Genome, Human | 1 | 2006 | 823 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2023 | 4560 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 215 | 0.040 |
Why?
|
| Cell Division | 1 | 2002 | 693 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 300 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1922 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2017 | 3829 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1190 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 756 | 0.040 |
Why?
|
| Tokyo | 1 | 2019 | 3 | 0.040 |
Why?
|
| France | 1 | 2019 | 53 | 0.040 |
Why?
|
| Face | 1 | 2020 | 109 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 756 | 0.040 |
Why?
|
| North America | 1 | 2019 | 195 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 12269 | 0.040 |
Why?
|
| Carbonic Anhydrase II | 1 | 2018 | 4 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2025 | 1264 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2018 | 39 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2011 | 211 | 0.040 |
Why?
|
| Gene Expression | 1 | 2002 | 1301 | 0.040 |
Why?
|
| Infant | 2 | 2017 | 3220 | 0.030 |
Why?
|
| Skull | 1 | 2020 | 270 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 570 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2002 | 630 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 105 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 5899 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2018 | 191 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2016 | 21 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2016 | 39 | 0.030 |
Why?
|
| Child | 2 | 2019 | 7355 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 119 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 526 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2016 | 40 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1170 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 134 | 0.030 |
Why?
|
| Benchmarking | 1 | 2016 | 80 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2017 | 196 | 0.030 |
Why?
|
| Reference Standards | 1 | 2016 | 146 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1546 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 192 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 413 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2016 | 248 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 962 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 841 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1948 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1524 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1464 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 700 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 894 | 0.030 |
Why?
|
| Animals | 2 | 2023 | 28155 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 1175 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 2755 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 295 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1931 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1621 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 9099 | 0.020 |
Why?
|
| United States | 1 | 2024 | 7622 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 469 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1173 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 5410 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3830 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2006 | 17 | 0.020 |
Why?
|
| Physical Chromosome Mapping | 1 | 2006 | 27 | 0.020 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2006 | 32 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 194 | 0.020 |
Why?
|
| Mosaicism | 1 | 2006 | 73 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2006 | 109 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2006 | 214 | 0.010 |
Why?
|
| Heterozygote | 1 | 2006 | 382 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 691 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 826 | 0.010 |
Why?
|
| Neoplasms | 1 | 2016 | 3169 | 0.010 |
Why?
|